BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2022

Apr 20, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2022-04-18

Reporting Person: ABERCROMBIE GEORGE B (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-04-18	Common Stock	M	5000	$3.32	Acquired	5000	Direct
2022-04-18	Common Stock	S	5000	$11.04	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-18	Automatic Stock Option Grant	$3.32	M	5000	Disposed	2022-05-23	Common Stock (5000)	Direct

Footnotes

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.

F2: The option vested 1/12 per month for a period of 12 months, beginning on June 23, 2012.